Safety and immunogenicity of a three-component blood-stage malaria vaccine (MSP1, MSP2, RESA) against Plasmodium falciparum in Papua New Guinean children-Reference-Cited by-同舟云学术

Safety and immunogenicity of a three-component blood-stage malaria vaccine (MSP1, MSP2, RESA) against Plasmodium falciparum in Papua New Guinean children

Published:2003-12 Issue:1 Volume:22 Page:30-41
ISSN:0264-410X
Container-title:Vaccine
language:en
Short-container-title:Vaccine

Author:

Genton Blaise,Al-Yaman Fadwa,Betuela Inoni,Anders Robin F,Saul Allan,Baea Kay,Mellombo Mata,Taraika Jack,Brown Graham V,Pye David,Irving David O,Felger Ingrid,Beck Hans-Peter,Smith Thomas A,Alpers Michael P

Publisher

Elsevier BV

Subject

Infectious Diseases,Public Health, Environmental and Occupational Health,General Veterinary,General Immunology and Microbiology,Molecular Medicine

Reference20 articles.

1. Efficacy of RTS,S/AS02 malaria vaccine against Plasmodium falciparum infection in semi-immune adult men in The Gambia: a randomised trial;Bojang;Lancet,2001

2. A blood-stage malaria vaccine (MSP1, MSP2, RESA) reduces Plasmodium falciparum density and exerts a selective pressure on parasite populations in a phase I/IIb trial in Papua New Guinea;Genton;J. Infect. Dis.,2002

3. Effect of vaccination with three recombinant asexual-stage malaria antigens on initial growth rates of Plasmodium falciparum in non-immune volunteers;Lawrence;Vaccine,2000

4. The Malaria Vaccine Epidemiology and Evaluation Project of Papua New Guinea: rationale and baseline studies;Alpers;PNG Med. J.,1992

5. Assessment of the role of naturally acquired antibody levels to Plasmodium falciparum merozoite surface protein-1 in protecting Papua New Guinean children from malaria morbidity;Al-Yaman;Am. J. Trop. Med. Hyg.,1996

Cited by 107 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Merozoite surface protein 2 polymorphism of Plasmodium falciparum isolates in a selected malarious area of Northwest Ethiopia;2024-07-18

2. Immune tolerance caused by repeated P. falciparum infection against SE36 malaria vaccine candidate antigen and the resulting limited polymorphism;Parasitology International;2024-04

3. Persistence of Anti-SE36 Antibodies Induced by the Malaria Vaccine Candidate BK-SE36/CpG in 5–10-Year-Old Burkinabe Children Naturally Exposed to Malaria;Vaccines;2024-02-06

4. Identification of Novel, Potent, and Selective Compounds against Malaria Using Glideosomal-Associated Protein 50 as a Drug Target;ACS Omega;2023-10-06

5. Identification of novel, potent, and selective compounds against malaria using Glideosomal Associated Protein 50 as a drug Target;2023-05-02